Up to 20% of patients with total joint
arthroplasty will develop radiographic evidence of aseptic loosening (AL), which most likely results from an inflammatory response to billions of wear debris shed from the implant. Our previous work has demonstrated that
erythromycin (EM), a
macrolide antibiotic, inhibits wear debris-induced inflammatory osteoclastogenesis through the reduction of
cytokine production and osteoclast differentiation, both of which involve the
NF-kappaB pathway. The aim of the current study was to determine whether EM inhibits wear debris-induced inflammatory
osteolysis in a murine
osteolysis model. Ultrahigh molecular-weight
polyethylene (
UHMWPE) debris was introduced into established air pouches on BALB/c mice, followed by implantation of calvaria bone from syngeneic littermates. EM (2 mg/kg/day) was given to mice intraperitoneally 2 days before
UHMWPE introduction and maintained until the sacrifice of the mice. Mice with and without EM treatment, as well as control mice injected with saline alone were included in this study. Pouch tissues were collected 14 days after
UHMWPE inoculation for molecular and histology analysis. Our findings indicate that: (1) EM reduced
UHMWPE-induced tissue
inflammation, including the diminished pouch membrane thickness, reduced inflammatory cellular infiltration, and lowered IL-1beta and
TNF-alpha expression (
mRNA and
protein); (2) EM inhibited
UHMWPE-induced osteoclastogenesis, with reduced gene activation of RANK, RANKL, and CPK, and diminished RANKL expression in
UHMWPE stimulated pouches, and (3) EM markedly reduced the number of TRAP(+) cells in pouch tissues, and protected against bone
collagen depletion. In conclusion, this study provides the evidence that EM inhibits the
UHMWPE particles-induced inflammatory
osteolysis in a murine model, and represents a promising therapeutic candidate for the prevention and treatment of AL.